Other Events ·
Nasdaq confirms Vivos Therapeutics complies with $2.5M stockholders' equity listing standard
VVOSVivos Therapeutics, Inc.
The Nasdaq Listing Qualifications staff notified Vivos Therapeutics that it currently meets the minimum stockholders’ equity requirement of $2.5 million under Listing Rule 5550(b)(1). This compliance follows a transaction with SOD Sciences, Inc., where the company issued Series C Convertible Preferred Stock with an aggregate stated value of $12 million, which is expected to increase equity by more than $10 million. Nasdaq warned that failure to demonstrate continued compliance in the next periodic report could result in delisting proceedings. Vivos Therapeutics operates as a medical technology and healthcare services company focused on developing diagnostic and treatment methods for obstructive sleep apnea.